IBDEI1BC ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22326,0)
 ;;=C92.A1^^87^981^11
 ;;^UTILITY(U,$J,358.3,22326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22326,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
 ;;^UTILITY(U,$J,358.3,22326,1,4,0)
 ;;=4^C92.A1
 ;;^UTILITY(U,$J,358.3,22326,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,22327,0)
 ;;=C92.A0^^87^981^12
 ;;^UTILITY(U,$J,358.3,22327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22327,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,22327,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,22327,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,22328,0)
 ;;=C92.51^^87^981^13
 ;;^UTILITY(U,$J,358.3,22328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22328,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,22328,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,22328,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,22329,0)
 ;;=C92.50^^87^981^14
 ;;^UTILITY(U,$J,358.3,22329,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22329,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,22329,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,22329,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,22330,0)
 ;;=C94.40^^87^981^17
 ;;^UTILITY(U,$J,358.3,22330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22330,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,22330,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,22330,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,22331,0)
 ;;=C94.42^^87^981^15
 ;;^UTILITY(U,$J,358.3,22331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22331,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,22331,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,22331,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,22332,0)
 ;;=C94.41^^87^981^16
 ;;^UTILITY(U,$J,358.3,22332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22332,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,22332,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,22332,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,22333,0)
 ;;=D62.^^87^981^18
 ;;^UTILITY(U,$J,358.3,22333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22333,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,22333,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,22333,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,22334,0)
 ;;=C92.41^^87^981^19
 ;;^UTILITY(U,$J,358.3,22334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22334,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,22334,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,22334,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,22335,0)
 ;;=C92.40^^87^981^20
 ;;^UTILITY(U,$J,358.3,22335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22335,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,22335,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,22335,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,22336,0)
 ;;=D56.0^^87^981^21
 ;;^UTILITY(U,$J,358.3,22336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22336,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,22336,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,22336,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,22337,0)
 ;;=D63.1^^87^981^23
 ;;^UTILITY(U,$J,358.3,22337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22337,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,22337,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,22337,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,22338,0)
 ;;=D63.0^^87^981^24
 ;;^UTILITY(U,$J,358.3,22338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22338,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
